Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

October 1st, 2019

AUTHORS
Even H. Rustad / Kristine Misund / Elsa Bernard / Eivind Coward / Venkata D. Yellapantula / Malin Hultcrantz / Caleb Ho / Dickran Kazandjian / Neha Korde / Sham Mailankody / Jonathan J. Keats / Theresia Akhlaghi / Aaron D. Viny / David J. Mayman / Kaitlin Carroll / Minal Patel / Christopher A. Famulare / Davine Hofste op Bruinink / Kasey Hutt / Austin Jacobsen / Ying Huang / Jeffrey E. Miller / Francesco Maura / Elli Papaemmanuil / Anders Waage / Maria E. Arcila / Ola Landgren

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

March 1st, 2024 Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

January 25th, 2024 Leveraging Standardized MRD Assays to Guide CLL Treatment

March 23rd, 2023 Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.